New Lenvima/Keytruda combo data in a range of cancers presented at ESMO 2020
pharmafile | September 21, 2020 | News story | Research and Development, Sales and Marketing | Cancer, ESMO2020, Eisai, Lenvima, MSD, keytruda
New data from two studies investigating the combination of Eisai’s multiple receptor tyrosine kinase inhibitor Lenvima (lenvatinib) and MSD’s blockbuster anti-PD-1 therapy Keytruda (pembrolizumab) were revealed at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.
In the first study, the combo was found to generate an objective response rate (ORR) of 21.4% in the treatment of unresectable or advanced melanoma which has progressed following anti-PD-1/PD-L1 therapy, representing 22 out of 103 patients.
This rate was found to be higher in those who had seen disease progression after receiving treatment with an anti-PD-1/L1 in addition to anti-CTLA-4 therapy, recorded at 31%, or nine of the 29 participants in this population.
Furthermore, median overall survival for the combo was demonstrated to be 13.9 months, with a nine-month overall survival rate of 65.4%.
In a separate Phase 2 study examining the efficacy of the combo in the treatment of ovarian, gastric, colorectal and biliary tract cancer, triple-negative breast cancer and glioblastoma multiforme, ORR was found to vary between 9.7% and 32.3%.
Miguel Marcão, Vice President of Eisai’s EMEA Oncology Business Group, said the data “represents important progress, particularly in advanced cancer types where treatment options can be severely limited for patients, leading to a high unmet need,” adding, “We remain committed to delivering on our strategic collaboration with Merck and exploring the potential of lenvatinib across multiple tumour types, to ensure we can help as many patients as possible.”
Matt Fellows
Related Content
TILT Biotherapeutics shares data on TILT-123 with Keytruda for ovarian cancer treatment
TILT Biotherapeutics has announced promising preliminary safety and efficacy data from its ongoing phase 1 …
Geneos Therapeutics shares data from phase 1/2 trial for cancer vaccine
Geneos Therapeutics has announced that it has published positive safety, immunogenicity and efficacy data from …
Curve Therapeutics’ CSO publishes research on HIF inhibition for cancer treatment
Curve Therapeutics has announced that its chief scientific officer, Professor Ali Tavassoli has published research …
